Wells Fargo & Company Downgrades Halozyme Therapeutics (NASDAQ:HALO) to Equal Weight
Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) was downgraded by equities research analysts at Wells Fargo & Company from an “overweight” rating to an “equal weight” rating in a research note issued on Monday, MarketBeat reports. They currently have a $62.00 price target on the biopharmaceutical company’s stock, up from their previous price target of […]
9 Oct 07:00 · The Markets Daily